Solid Tumours
Conditions
Keywords
solid tumors, lymphoma, Phosphoinositide 3-kinase inhibitor
Brief summary
P3K112826 is a Phase I, first-time-in-human dose escalation study in subjects with refractory malignancy. The primary objective of this study is to determine the recommended Phase II dose of GSK2126458 based on safety and tolerability, pharmacokinetics, pharmacodynamics and preliminary evidence of clinical activity. Secondary objectives are to characterize the pharmacokinetics of GSK2126458; and to explore relationships between GSK2126458 pharmacokinetics, pharmacodynamics, response prediction biomarkers and clinical endpoints.
Detailed description
This study is a Phase I, first-time-in-human dose escalation study in subjects with refractory solid tumors or lymphoma. The primary objective of this study is to determine the recommended Phase II dose of GSK2126458 based on safety and tolerability, pharmacokinetics, pharmacodynamics and preliminary evidence of clinical activity. Secondary objectives are to characterize the pharmacokinetics of GSK2126458; and to explore relationships between GSK2126458 pharmacokinetics, pharmacodynamics, response prediction biomarkers and clinical endpoints. Subjects with solid tumors or lymphoma will initially receive oral GSK2126458 daily for 28 consecutive days in each 28 day cycle. Subjects may be dosed once or twice a day or may be dosed on an intermittent schedule depending on the safety, pharmacokinetic and pharmacodynamic results that become available as the study progresses. The starting dose will be 0.1 mg once a day. Expansion of some cohorts will be conducted to test tumor pharmacodynamics, further explore the toxicity profile and to look for preliminary evidence of activity in subjects with tumors with PIK3CA mutations. The recommended Phase II dose will be the lowest dose explored (at or below MTD) that maintains biologic activity with an acceptable tolerability profile.
Interventions
DRUGGSK2126458
GSK2126458 is an experimental treatment for patients with cancer.
Sponsors
GlaxoSmithKline
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically- or cytologically- confirmed diagnosis of solid tumor malignancy, or lymphoma * Performance Status score of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG) scale. * Female or male that is willing to take measures to avoid pregnancy in self or a partner, including abstinence, or double barrier method. * Adequate organ system function
Exclusion criteria
* Use of an investigational anti-cancer medication within 28 days or 5 half-lives preceding the first dose of GSK2126458. * Chemotherapy within the last 3 weeks (6 weeks for prior nitrosourea or mitomycin C * Any major surgery, radiotherapy, or immunotherapy within the last 4 weeks. * Prior use of any PI3K inhibitor. * Current use of a prohibited medication or requires any of these medications during treatment with GSK2126458. * Presence of an active gastrointestinal disease or other condition known to interfere significantly with the absorption, distribution, metabolism, or excretion of drugs. * Unresolved toxicity greater than Grade 1 from previous anti-cancer therapy except alopecia. * QTc interval ≥ 480 msecs. * History of acute coronary syndromes; Class II, III, or IV heart failure; stroke or subarachnoid hemorrhage. * Systolic blood pressure (SBP) of ≥140 mmHg or diastolic blood pressure (DBP) of ≥ 90mmHg. * Previously diagnosed Type 1 diabetes mellitus. Subjects with Type 2 diabetes are prohibited in the dose escalation part of the study. * Symptomatic or untreated leptomeningeal or brain metastases. * Primary malignancy of the central nervous system.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events (AEs) and changes in laboratory values and vital signs. Pharmacokinetic parameter values for GSK2126458, Change from baseline in protein markers in tumor and/or blood. Blood glucose and insulin levels. Tumor response, RECIST defined | Subjects continue on study until disease progression or consent withdrawal |
Secondary
| Measure | Time frame |
|---|---|
| Metabolic profile in plasma at the maximum tolerated dose | Subjects continue on study until disease progression or consent withdrawal |
Countries
Netherlands, United States
Outcome results
None listed